Chapter 1 Executive Summary
Chapter 2 Introduction
2.1 Non-Opioids in Pain Management
2.1.1 Analgesics
2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
2.2.1 Pharmacological Actions of the NSAIDs
2.2.2 The Prostaglandin Pathway
2.2.3 NSAIDS, gastric injury and U.S. healthcare expenditure
2.2.3.1 Risk factors
2.2.3.2 Skin reactions
2.2.3.3 Adverse renal effects
2.3 Acetylsalicylic Acid (Aspirin), Acetaminophen (Paracetamol) and the NSAIDs
2.3.1 Salicylates
2.3.1.1 Pharmacokinetics
2.3.2 Acetaminophen
2.3.3 Propionic Acid Based NSAIDs
2.4 Top Four Products in the Non-Narcotics Market and Market Share, 2006
2.4.1 Advil (Ibuprofen, Wyeth)
2.4.2 Tylenol (Paracetamol, J&J)
2.4.3 Aspirin Bayer (Acetylsalicylic Acid, Bayer)
2.4.4 Efferalgan (Paracetamol, Bristol-Myers Squibb)
Chapter 3 The Non-Opioid Market
3.1 The Global Non-Opioid Market Analysis
3.1.1 Tylenol Set to Reach Blockbuster Status
3.1.2 Aspirin Bayer - Huge Amount of Line Extensions Keeping Sales Up
3.1.3 Advil Set to Become Top Product in the Non-Narcotics Market
3.2 Safety Issues Affect Non-Opioid Drugs
3.2.1 Acetaminophen Linked to Liver Damage
3.3 Visiongain Believes That Significant Advances Will Occur in this Market With Potentially High Revenues for Next-Generation Products
3.4 The Withdrawal of Vioxx and Safety Concerns Over COX-2 Inhibitors Have Played a Role in the Increased Sales of Aspirin and Ibuprofen
3.5 Johnson & Johnson Currently Leads the Non-Opioid Market
3.6 Efferalgan will be Overtaken by Advil as the Leading Non-Opioid Product
3.7 The Top Ten Countries in the Non-Opioid Market
Chapter 4 Forces Affecting the Non-Opioid Market
4.1 SWOT Analysis of the Non-Opioid Market
4.1.1 Market Drivers
4.1.2 Market Restraints
4.2 NSAIDs – Coxibs (SWOT analysis)
4.2.1 Common unwanted effects
4.2.2 Gastrointestinal disturbances
4.2.3 SWOT Analysis of the NSAIDs - COX-Inhibitors
4.3 Lack of Adequate Reimbursement Limits Potential of Non-Opioid Drugs in Pain Management
4.4 Patients Dependent on Reformulations of Existing Drugs
4.5 The Undertreatment of Pain
4.5.1 How Might These Findings Affect the Non-Opioid Market for Pain Management Pharmaceuticals?
4.6 The Non-Opioid Market Will See Three Blockbuster Drugs: Visiongain Predicts
Chapter 5 Pipeline Developments in the Non-Opioid Market for Pain
5.1 Agents in Phase II of Clinical Development
5.1.1 Johnson&Johnson’s SCIO 469
5.1.2 Merck’s MK 0686, MK 0759 and MK 2295
5.1.3 GSK’s 681323 and 705498
5.1.4 Sosei’s AD 337
5.2 Agents in Phase III of Clinical Development
5.2.1 Biovail’s BVF 146
5.2.2 Sanofi’s Saredutant (SR 48968)
5.2.3 Endo’s Ketoprofen
5.2.4 GSK’s 406381
5.3 Discussion of Current Pipeline Developments
Chapter 6 Conclusion
6.1 Pain is a Serious Condition with High Prevalence
6.2 Why the Non-Opioid market is More Successful than the Opioid Market in Pain Management
6.3 The Global Non-Opioid Market Will Expand Strongly from 2007 to 2012
6.4 Market Drivers
6.5 Market Restraints
6.6 Geographical Breakdown of Revenues in the Non-Opioid Market
6.6.1 Sales of Non-Opioid Drugs Will Rise Steadily in the US from 2007 to 2012
6.6.2 France Will Have the Second-Highest Sales of Non-Opioid Drugs
6.7 There are Promising Developments Currently in Mid to Late Stage Clinical Testing
6.8 Outlook for the Future of Pain Management
Appendix A: Sales Data 2006
Appendix B: About Visiongain
Appendix C: Visiongain Report Evaluation Form
TABLES
Table 1.1 Top Non-Opioid Products Revenue Forecast ($m), 2007-2012
Table 2.1 Classes of Traditional NSAIDS
Table 2.2 Top Four Products in the Non-Narcotics Market and Revenue, 2006
Table 3.1 The Total World Non-Narcotics Products Market Forecast ($m), 2007-2022
Table 3.2 Tylenol Market Forecast ($m), 2007-2012
Table 3.3 Aspirin Bayer Market Forecast ($m), 2007-2012
Table 3.4 Advil Market Forecast ($m), 2007-2012
Table 3.5 Top 10 Leading Companies in the Non-Opioid Market and Market Share, 2006
Table 3.6 Top Ten Countries in the Non-Opioid Market Revenue ($m) Forecast 2007-2012
Table 4.1 SWOT Analysis of the Non-Opioid Market
Table 4.2 SWOT Analysis of the COX- Inhibitors
Table 5.1 Summary of Pipeline Products Phase II and Above, 2007
Table 6.1 Geographical Breakdown of Revenues in the Non-Opioid Market ($m), 2006-2012
GRAPHS
Graph 3.1 The World Non-Narcotics Market Revenue Forecast ($m), 2007-2022
Graph 3.2 Tylenol Revenue Forecast ($m), 2007-2012
Graph 3.3 Aspirin Bayer Revenue Forecast ($m), 2007-2012
Graph 3.4 Advil Revenue Forecast ($m), 2007-2012
Graph 3.5 Top 10 Leading Companies in the Non-Opioid Market ($m), 2006
Graph 6.1 Total Sales of Non-Opioid Drugs ($m), 2007-2022
Graph 6.2 Sales of Leading Non-Opioid Drugs ($m), 2007-2012
CHARTS
Chart 3.1 Leading Companies in the Non-Opioid Market, Market Share (%), 2006
Chart 3.2 Top Countries in the Non-Opioid Market, Market Share (%), 2006
Chart 3.3 Top Countries in the Non-Opioid Market, Market Share (%), 2009
Chart 3.4 Top Countries in the Non-Opioid Market, Market Share (%), 2012